Theranostics Products was Radnostix’s largest segment in fiscal 2025, bringing in $6.84M of $13.07M (52%).
| Segment | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Theranostics Products | $707.76K | $6.84M | $8.01M | $6.84M | |||||
| Nuclear Medicine Products | $7.15M | $4.39M | — | — | |||||
| Calibration Reference Products | — | — | $3.52M | $4.25M | |||||
| Radiochemical Products | — | — | — | — | |||||
| Cobalt Products | $2.29M | $1.04M | $2.37M | $1.75M | |||||
| Radiological Services | — | — | — | — | |||||
| Fluorine Products | — | — | — | — | |||||
| Medical Device Products | — | — | $8.66K | $228.95K | |||||
| Total | $10.15M | $12.27M | $13.90M | $13.07M |
Radnostix brought in $13.07M from its four segments in fiscal 2025, the year ended December 31, 2025. That was down 6.0% from $13.90M in fiscal 2024. Theranostics Products was the largest at $6.84M (52.3%), ahead of Calibration Reference Products at $4.25M (32.5%) and Cobalt Products at $1.75M (13.4%). The remaining segment, Medical Device Products, brought in $228.95K.
Compared with fiscal 2024, Calibration Reference Products grew fastest, up 20.7% to $4.25M, while Cobalt Products fell the most, down 25.9% to $1.75M.
Radnostix began breaking out Calibration Reference Products in fiscal 2024 and Medical Device Products in fiscal 2024. Radnostix stopped reporting Nuclear Medicine Products as a separate segment after fiscal 2023, when it brought in $4.39M.
United States was Radnostix’s largest region in fiscal 2022, bringing in $5.34M of $6.14M (87%).
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 |
|---|---|---|---|---|---|---|
| United States | — | — | $3.77M | $5.34M | ||
| U.S | $3.07M | $3.58M | — | — | ||
| Non-Us | — | — | — | $804.93K | ||
| Outside U.S | $858.54K | $783.27K | $907.48K | — | ||
| Total | $3.93M | $4.37M | $4.68M | $6.14M |
Radnostix brought in $6.14M from its two regions in fiscal 2022, the year ended December 31, 2022. Radnostix regrouped these regions after fiscal 2021, so the total does not compare directly with that year's $4.68M. United States was the largest at $5.34M (86.9%), ahead of Non-Us at $804.93K (13.1%).
Radnostix began breaking out United States in fiscal 2021 and Non-Us in fiscal 2022. Radnostix stopped reporting U.S ($3.58M in fiscal 2020) and Outside U.S ($907.48K in fiscal 2021) as separate regions.
Radnostix (INIS) reports its revenue by segment and by geography. In fiscal 2025, Theranostics Products was its largest segment, bringing in $6.84M (52.3% of the total), followed by Calibration Reference Products at $4.25M (32.5%).
Theranostics Products was Radnostix's largest segment in fiscal 2025, bringing in $6.84M, or 52.3% of the $13.07M total across its four segments.
United States was Radnostix's largest region in fiscal 2022, bringing in $5.34M, or 86.9% of the $6.14M total across its two regions.
Among Radnostix's segments that make up at least 2% of revenue, Calibration Reference Products grew fastest in fiscal 2025, up 20.7% from $3.52M to $4.25M.
Every figure comes from Radnostix's annual financial filings, as reported. Each line keeps the name Radnostix gives it, and years follow its fiscal calendar.
Radnostix's revenue by segment goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.